Dr Reddy's launches anti-fungal ointment in the US
The company's shares were trading down 0.3% on the BSE from previous close.
Dr Reddy's Laboratories Ltd announced the launch of anti-fungal ointment nystatin and triamcinolone acetonide in the US market.
In a BSE filing, Dr Reddy's Laboratories Ltd said, "It has launched nystatin and triamcinolone acetonide cream USP, in the United States market, approved by the US Food and Drug Administration (USFDA)."
The product is the generic equivalent of nystatin and triamcinolone acetonide cream, USP 1,00,000 units/g-0.1% manufactured by Taro Pharmaceuticals USA Inc, it added.
Quoting IMS Health sales data, Dr Reddy's Laboratories said that for the 12-month period ending October 2016, the generic had US sales of around $119 million.
Dr Reddy's Laboratories' shares today were trading at Rs 3,178.70 in the morning trade on the BSE, down 0.03%.